
    
      The primary objective of this Phase III study is the evaluation of therapeutic equivalence of
      HX575 Hexal AG and a comparator of epoetin alfa, ERYPOÂ® in the maintenance intravenous
      treatment of renal anemia. Efficacy, dosage and safety of HX575 Hexal AG in the long-term
      treatment were assessed.
    
  